A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Inclusion Criteria: * 1\) A patient who has been diagnosed with insulin resistance syndrome (type A, type B, type non-A non-B) or lipoatrophic diabetes mellitus prior to obtaining consent * 2\) A patient who has received consistent dosage and administration of drugs aiming a hypoglycemic effect and consistent instructions of diet therapy/exercise therapy for more than 12 weeks before enrollment * 3\) A patient with \>= 7.0 % of HbA1c at the time of screening * 4\) A patient, if taking other SGLT2 inhibitor than empagliflozin, whose SGLT2 inhibitor can be washed out for more than 12 weeks prior to starting empagliflozin * 5\) A patient at the age of \>=20 years at the time of consent * 6\) A patient who has received sufficient explanation with regard to information such as the objectives and details of this study, expected drug efficacy/pharmacological action, and risks, and has given written consent by her/himself. Exclusion Criteria: * 1\) A patient with a medical history of acute coronary syndrome (including non-ST-elevation myocardial infarction, ST-elevation myocardial infarction, and unstable angina pectoris), stroke or transient ischemic attack (TIA) within 3 months before obtaining consent * 2\) A patient with suspected hepatic dysfunction, that either of serum ALT, AST or alkaline phosphatase in the screening period is exceeding 3-fold of upper limit of normal rang * 3\) A patient who is receiving a systemic steroid at the time of consent (except for type B) * 4\) …